MONTREAL, QUEBEC--(Marketwire - October 01, 2008) - Ambrilia Biopharma Inc. (TSX: AMB) today reported positive 24-week extension Phase III ("Study 302") top line results for its proprietary prolonged-release formulation of octreotide C2L. Overall, the results support the safety of C2L over an additional period of 6 months. In addition, the efficacy as measured by the mean Insulin-like Growth Factor 1 ("IGF-1") and Growth Hormone ("GH") plasma levels is maintained at the same level throughout the study period. It further confirms that octreotide C2L 30 mg every 6 weeks can replace Sandostatin®LAR 30 mg every 4 weeks in acromegalic patients, with the same clinical benefit and no unexpected or serious adverse effects.
